CN100491355C - 带有五元环基团的环状二胺化合物 - Google Patents

带有五元环基团的环状二胺化合物 Download PDF

Info

Publication number
CN100491355C
CN100491355C CNB02813110XA CN02813110A CN100491355C CN 100491355 C CN100491355 C CN 100491355C CN B02813110X A CNB02813110X A CN B02813110XA CN 02813110 A CN02813110 A CN 02813110A CN 100491355 C CN100491355 C CN 100491355C
Authority
CN
China
Prior art keywords
trimethoxyphenyl
yield
400mhz
lower alkyl
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02813110XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1522250A (zh
Inventor
儿玉龙彦
田村正宏
小田敏明
山嵜行由
西川雅大
土肥武
京谷善德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN1522250A publication Critical patent/CN1522250A/zh
Application granted granted Critical
Publication of CN100491355C publication Critical patent/CN100491355C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Surface Treatment Of Glass Fibres Or Filaments (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB02813110XA 2001-06-29 2002-06-27 带有五元环基团的环状二胺化合物 Expired - Fee Related CN100491355C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/893,682 US6472386B1 (en) 2001-06-29 2001-06-29 Cyclic diamine compound with 5-membered ring groups
US09/893,682 2001-06-29

Publications (2)

Publication Number Publication Date
CN1522250A CN1522250A (zh) 2004-08-18
CN100491355C true CN100491355C (zh) 2009-05-27

Family

ID=25401912

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02813110XA Expired - Fee Related CN100491355C (zh) 2001-06-29 2002-06-27 带有五元环基团的环状二胺化合物

Country Status (11)

Country Link
US (1) US6472386B1 (enExample)
EP (1) EP1400515B1 (enExample)
JP (1) JP4225895B2 (enExample)
KR (1) KR100878421B1 (enExample)
CN (1) CN100491355C (enExample)
AT (1) ATE464295T1 (enExample)
CA (1) CA2451238C (enExample)
DE (1) DE60235980D1 (enExample)
ES (1) ES2341945T3 (enExample)
TW (1) TWI315307B (enExample)
WO (1) WO2003002540A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US7115646B2 (en) * 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
JP4634303B2 (ja) * 2003-10-10 2011-02-16 興和株式会社 血管新生抑制薬
MXPA06012683A (es) * 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
BRPI0511250A (pt) 2004-05-17 2007-11-27 Otsuka Pharma Co Ltd composto de tiazol e uso deste
WO2008045663A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
JP5571062B2 (ja) 2008-03-19 2014-08-13 バイエル・クロップサイエンス・アーゲー 殺真菌剤ヒドロキシモイル−テトラゾール誘導体
CN103562379A (zh) * 2011-05-19 2014-02-05 国立大学法人德岛大学 细胞分化诱导剂以及分化诱导方法
EP2890686B1 (en) * 2012-08-30 2017-01-04 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
US10189864B2 (en) 2016-02-19 2019-01-29 Lawrence Livermore National Security, Llc Metal complexes based on a bis(2-pyridylmethyl)amine-based scaffold and methods of making the same
US10112912B2 (en) * 2016-03-02 2018-10-30 Lawrence Livermore National Security, Llc Homopiperazine-based catalysts for neutralization of organophosphorus-based compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723465A (en) * 1995-11-20 1998-03-03 Kowa Co., Ltd. Inhibitors for cell adhesion and cellular infiltration
JP2000086641A (ja) * 1998-09-11 2000-03-28 Kyorin Pharmaceut Co Ltd 2−置換ベンゾチアゾール誘導体及びその製造法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000065102A (ko) 1996-04-30 2000-11-06 게리 디. 스트리트, 스티븐 엘. 네스비트 2,6-디-알킬-4-실릴-페놀을사용한혈관세포흡착분자-1의억제방법및만성염증성질병의치료방법
JP3577183B2 (ja) 1996-06-17 2004-10-13 花王株式会社 動脈硬化症予防・治療剤
JPH10147568A (ja) 1996-11-19 1998-06-02 Mitsui Chem Inc ナフタレン誘導体およびそれを有効成分として含有する医薬品
JPH10182550A (ja) 1996-12-25 1998-07-07 Mitsui Chem Inc ヒドロキシ安息香酸誘導体およびそれを有効成分として含有する医薬品
JP4139453B2 (ja) 1997-09-24 2008-08-27 興和株式会社 細胞接着阻害剤
JP2000319277A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723465A (en) * 1995-11-20 1998-03-03 Kowa Co., Ltd. Inhibitors for cell adhesion and cellular infiltration
JP2000086641A (ja) * 1998-09-11 2000-03-28 Kyorin Pharmaceut Co Ltd 2−置換ベンゾチアゾール誘導体及びその製造法

Also Published As

Publication number Publication date
CN1522250A (zh) 2004-08-18
ES2341945T3 (es) 2010-06-30
EP1400515B1 (en) 2010-04-14
EP1400515A1 (en) 2004-03-24
WO2003002540A1 (fr) 2003-01-09
ATE464295T1 (de) 2010-04-15
CA2451238A1 (en) 2003-01-09
JP4225895B2 (ja) 2009-02-18
EP1400515A4 (en) 2004-11-24
TWI315307B (enExample) 2009-10-01
US6472386B1 (en) 2002-10-29
JPWO2003002540A1 (ja) 2004-10-14
HK1065029A1 (en) 2005-02-08
KR20040015737A (ko) 2004-02-19
KR100878421B1 (ko) 2009-01-13
CA2451238C (en) 2011-01-04
DE60235980D1 (de) 2010-05-27

Similar Documents

Publication Publication Date Title
JP5408434B2 (ja) アミド化合物
JP4120586B2 (ja) 2−アシルアミノチアゾール誘導体又はその塩
JP6360147B2 (ja) グリコシダーゼ阻害剤
TWI409062B (zh) 作為5-ht2a5-羥色胺受體之調節子而有用於與該受體有關的疾病之治療之3-苯基吡唑衍生物
TWI415845B (zh) 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
US8450317B2 (en) CXCR3 receptor antagonists
ES2375586T3 (es) Derivados de imidazolidinona.
TWI313266B (en) Thiazoline derivatives and pharmaceutical composition containing the same
CZ20022072A3 (cs) Nepeptidylové inhibitory VLA-4 dependentní buněčné vazby použitelné pro léčbu zánětlivých, autoimunitních a respiračních onemocnění
AU2012208693B2 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
KR100386392B1 (ko) 아졸유도체및이를포함하는약제학적조성물
JP6076498B2 (ja) ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン
JP2021522253A (ja) 化合物及びその使用
WO2004087641A1 (ja) ヒドラゾン誘導体
SK20052000A3 (sk) Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb
WO2019191327A1 (en) Ox2r compounds
KR20150120516A (ko) 2-아실아미노티아졸 유도체 또는 그의 염
US20050234029A1 (en) Compounds
KR100878421B1 (ko) 5원 환식기를 가지는 환상 디아민 화합물
RU2389718C2 (ru) Новые производные гексафторизопропанола
TW448163B (en) New 1,2,5-trisubstituted 1,2-dihydroindazol-3-ones having anti-asthmatic, anti-allergic, anti-inflammatory, immunomodulating and neuroprotective action, process for their preparation and their use as medicaments
CA3162388A1 (en) 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorder
US20200115338A1 (en) Novel compounds
EP0775139A1 (en) Imidazopyridine derivatives as dual histamine (h1) and platelet activating factor (paf) antagonists
TW201245187A (en) Pyrazole derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090527

Termination date: 20120627